In 2008, the District of Columbia (DC) Department of Health and the NIH launched the DC Partnership for HIV/AIDS Progress, a collaborative research initiative designed to decrease the rate of new HIV infections in the city, improve the health of district residents living with HIV infection, and strengthen the city's response to the HIV/AIDS epidemic. This programme was developed to address the high level of incident HIV infections in the city using state of the art research as the tool. The initial focus was to determine the true status of disease burden in the city. To accomplish this, we created the DC Cohort, which has now collected longitudinal clinical data from approximately 8000 consented HIV-infected outpatients receiving care at 13 treatment clinics in DC. Additionally, through the HIV Prevention Trials Network, a series of clinical trials brought the current state of the art prevention research to the city residents. Combined with public health campaigns aimed at educating city residents, the city has vastly improved treatment coverage and has reduced HIV incidence. In addition, the programme has been seeking ways to better understand HIV/HCV co-infection and has sought to expand HCV treatment options for this population. Through a number of clinical studies we demonstrated how sustained HCV suppression could be reliably obtained in this co-infected population. Further we found that HCV treatment was a gateway for reaching what many public health officials believed was the most difficult population to identify and engage -dually infected people. Further work has focused on defining how best to deliver HCV treatment. The ASCEND study, launched in 2015, examined whether primary care physicians and other healthcare providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with HCV infection. Validation of this task shifting provides an important piece of information as we advance our plans for HCV eradication.
O112
Towards and HIV cure: a clinician's perspective Steven G. Deeks University of California, San Francisco, CA, USA Given the challenge of delivering complex, expensive and potentially harmful antiretroviral therapy (ART) on a global level, there is intense interest in the development of short-term, well-tolerated regimens that will either fully eradicate all HIV (a "cure") or durable prevent HIV replication in absence of any therapy (a "remission"). Recent heroic interventions such as hematopoietic stem cell transplant suggest that dramatic reductions in the reservoir size can be achieved, but that complete eradication will be challenging. Also, failure to eradicate on HIV is associated with risk of delayed rebounds in viremia, which can have detrimental effects to the HIV-infected person and his or her partners.
Most experts agree that a remission will be easier to achieve than a complete cure. Enthusiasm for this approach is supported by observations made in "elite" controllers and perhaps the rare and still controversial post-treatment controllers. Observations from these studies suggest that a sustained remission will likely require a low reservoir size and a potent and durable HIV-specific immune response. Enthusiasm for a remission is also being driven by success using immunotherapies to reduce and control cancer cells. Cancer and HIV persistence share a number of similarities. In each case, a rare population of cells with the capacity to cause harm becomes established in difficult to reach tissues. The local environment in each case is reshaped to prevent immune mechanisms from clearing the diseased cell. Specifically, a chronic inflammatory environment stimulates and immunosuppressive response and therapies that target these immune pathways have either been very successful (in cancer) or now entering the clinic (in HIV disease). These interventions have the potential to enable successful repurposing of preventative vaccines into the HIV cure arena. Efforts to cure or durably control HIV are now entering an era of experimental medicine in which the agenda will be increasingly driven by studies performed in non-human primates and early proof-of-concept clinical studies. Recent progress in these studies will be summarized. A pathway towards testing of viable combination regimens that have the chance to achieve a durable remission will also be discussed.
O122 HIV/AIDS guidelines on cART -the Brazilian perspective
Adele Schwartz Benzaken Brazil AIDS Programme, Rio de Janeiro, Brazil Brazil has recently incorporated dolutegravir (DTG) in both first and third line ART regimens in the Brazilian Unified Health System (SUS). Darunavir use was also extended as a preferable protease inhibitors (PI) in the second line, alongside its use in the third line. TDF/3TC/DTG is the preferable scheme for people living with HIV/AIDS (PLWHA) starting in 2017. TDF/3TC/EFZ is chosen for pregnant women and TB-HIV co-infection, without criteria of severity. PLWHA with tuberculosis can undergo TDF/ 3TC/RAL scheme whenever one of the conditions are presented: CD4 <100 cells/mm 3 , concomitant opportunistic infection, need of hospitalization/serious illness or disseminated TB. Regimens containing EFV are the initial choice for cART in cases of intolerance or whenever DTG is contraindicated. The safe use of ABC is corroborated by the incorporation in the SUS of the HLA B*5701 test. For the PI, ATV is the preferred one, followed by DRV and LPV, all boosted with ritonavir. The innovation is that DRV, previously administered to PLWHA with multiple ARV schemes exposures, can be used in the second line regimens. The Brazilian policy on cART poses challenges still to be solved: (i) the use of raltegravir for late presenter pregnant women living with HIV/AIDS, (ii) drug switch (phase out of nevirapine, fosamprenavir, indinavir, lopinavir and saquinavir) and (iii) new paediatric formulations (DTG). Implementing these guidelines and policies takes into account national budget and new ART, considering cost in the long run and its sustainability as a public health policy.
O123 ARV guidelines in Argentina
Carlos Zala HIV/AIDS Programme, Buenos Aires, Argentina Antiretroviral therapy in Argentina is free of charge to all eligible HIV infected individuals seeking for HIV care. According to current local guidelines, ARV treatment should be offered to subjects with a confirmed HIV infection regardless their CD4 T cell count. As of December 2016, approximately 50,000 PLWH were receiving ARVs through the National Programme. An additional 20,000 were being covered by the social security and private sector. At the three healthcare sectors, there are ARVs available within the four mayor drug classes, including generics drugs of nucleosides, nonnucleosides and protease inhibitors. The choice of an initial regimen is requested at the Programme by a registered physician within the available options recommended by the Argentinean Society of Infectious Diseases. Accordingly, an NNRTI, or boosted ritonavir protease inhibitor, or integrase inhibitor in combination with two analogue nucleosides are within the available regimens. A national wide survey has recently showed an increase number of primary HIV resistance, mainly to the NNRTIs. Figures close to the 10% prompted to the HIV/AIDS Programme to make available resistance testing prior to initiation of ARV therapy to subjects willing to start an efavirenz based regimen. The need of implementing timely results of resistance testing to newly HIV infected individuals across the country imposes a formidable challenge to the healthcare system. In this scenario, widely access to affordable new drugs, that is integrase inhibitors, should be considered.
O131
Treatment of hepatitis C: "where are we now?"
Mário Guimarães Pessoa University of São Paulo School of Medicine, São Paulo, SP, Brazil
In this lecture, we are going to talk about the management of patients with chronic HCV infection in this new era of highly effective direct-acting antivirals (DAAs). We came from a time of SVR rates of around 60% in the former difficult to treat genotype 1 patients with a poor tolerance to interferon treatment, to achieving a cure in more than 95% of them with few adverse events, with only 12 weeks of treatment in the majority of patients. Patients naïve to treatment with mild fibrosis and low viral load can even be treated with a shorten regimen of 8 weeks. Genotype 3 HCV infection is now the more difficult to cure, especially in patients with cirrhosis, but new combinations of DAAs are under development and we had the opportunity to see very good preliminary results in this population presented at the last AASLD meeting. Most of Latinamerican countries are prioritizing treatment only for patients with advanced liver disease, for budgetary reasons, but we expect in the near future to see more and more patients achieving the cure of this life-threatening infection, before becoming at high risk of hepatocellular carcinoma.
O132
Retreatment of patients failing AAD therapy in Spain in a real life setting: updated results from the HEPCREsp GEHEP004 cohort Introduction and aims: To describe the virological characteristics of patients failing approved DAA regimens in ithe HCVREsp-GEHEP004 Cohort in Spain, how they have being retreated and how were efficacy rates of retreatment. Methods: HCVREsp-GEHEP004 is a prospective multicentre cohort enrolling HCV infected patients treated with IFN-free DAA regimens at discretion of the investigators. Population-based sequencing of HCV NS3, NS5A and NS5B genes was performed. After receiving a comprehensive resistance interpretation report, the retreatment regimen was chosen. Results: HCVREsp includes 5521 patients treated with DAAs across Spain. Data of 277 failing patients (GT-1a (n = 96), Gt-1b (n = 81), GT3a (n = 60), GT-4a (n = 9), GT-4d (n = 31)) are shown. Patients had failed SOF/SIM (18.8%), SOF/DCV (18.4%), SOF/LDV (42.2%) or paritaprevir/ombitasvir ± dasabuvir (15.2%). Patients failing SOF/SIM developed RASs in NS3 in 74% of the GT1a infected patients and 52% of the GT1b, being RASs in position 168 the most prevalent. To date, 41/53 patients failing SOF/SIM have been retreated, 39 with Harvoni and 25 have reached 12 weeks post end of treatment: 22 patients (88%) have achieved SVR12. Almost all the patients failing SOF/DCV showed NS5A RASs, being Y93H highly prevalent in GT-1b (77.8%) and GT-3a (75.0%); to date, 22/48 patients failing SOF/DCV have been retreated, 11 have reached 12 weeks post end of treatment: 7 patients (58%) have achieved SVR12. Patients treated with SOF/LDV also showed a high prevalence of Y93H at failure, especially GT-1b (81.0%), in contrast to GT-3a infected patients (only 11.7% prevalence); of note, three GT-4 patients failing SOF/LDV harboured S282T. To date, 52/112 patients failing SOF/LDV have been retreated, 42% with SOF/SIM, 21 have reached 12 weeks post end of treatment: 18 patients (86%) have achieved SVR12. Most patients treated with 2D/3D developed RASs, and 14.2% showed RASs against the three drugs; almost a half of the patients failing 3D/2D (7/16) have been retreated. Conclusions: Genotype 1a and 1b patients failing DAAs in Spain harbour a high prevalence of RASs, especially in NS5A. Genotype 3 patients failing SOF/LDV are less prone to develop NS5A RASs than SOF/DCV failures. Retreatment of Sof/DCV failing patients was more difficult than SOF/LDV or SOF/SIM, with lower rates of SVR12.
Resistance testing may help to guide the retreatment option.
O133
Increased age-adjusted mortality and incidence of non-AIDS defining events among people living with HIV enrolled after 50yo and aging in care in Latin America. A CCASAnet cohort study 9 and Juan Sierra-Madero
Introduction: The proportion of people living with HIV (PLWH) older than 50 years is increasing in our region. The growth of this population will increase demands on healthcare systems as comorbidities are expected to rise. This study aims to quantify the frequency of non-AIDS associated comorbidities (NADEs) amongst aging people receiving care for HIV in CCASAnet centres between 2000 and 2015. We also explored whether the incidence of NADEs differs by age at enrolment (<50 years old (yo) and ≥50 yo) in patients of similar age. Methods: We selected HIV-infected adults between 50 yo and 65 yo receiving care in CCASAnet cohort centres between 2000 and 2015. We divided participants in two groups based on age at enrolment in care (<50 and ≥50 yo). We compared mortality between both groups and estimated the frequency of NADEs (cardio-and cerebro-vascular diseases, type 2 Diabetes mellitus "DM2," hypertension and non-AIDS-related neoplasias) in each group using Kaplan-Meier (KM) curves. We used inverse probability weights techniques and stratification by age-group to adjust for confounders and selection bias. We adjusted by gender, route of transmission, time since diagnosis to art, CD4 count at 50 and age. Results: 4788 patients over 50 years from seven Latin American countries were included. People enrolled in care ≥50 yo (n = 2010, 42%) had a significantly higher crude and adjusted mortality than those <50 yo at enrolment (n = 2788, 58%) ( Figure 1 ). Follow-up information on clinical events was collected for only 2937 patients. Amongst those, there was a higher incidence of DM2, cardiovascular events and non-AIDS-related neoplasias in people enrolled ≥50 yo when compared with those enrolled <50 yo ( Figure 2 ). A high number of diabetes and other events were diagnosed right after enrolment in care in patients enrolled after 50 yo.
Conclusions: PLWH enrolled in care in CCASAnet sites after 50 yo have an increased age-adjusted mortality, and incidence of NADEs than those reaching 50 yo in care. In addition to prevalent comorbidities at 50 yo or at enrolment in care after 50 yo, a large proportion of PLWH receiving care in our sites develop chronic NADE while in care. Higher incidence of Non AIDS related morbidity in patients enrolled after 50 yo may reflect a lack of clinical care in this population and the need of planning provision for complex, primary care for adults living with HIV older than 50 yo in our region.
O142
The 90s in the Americas: treatment ) below 10% amongst newly diagnosed individuals was also included. Unfortunately, 35% of new cases were diagnosed late in the course of the infection. In 2013, 79% of patients on first-line were being prescribed a WHO-recommended regimen (preferred or alternative). In 2013, 31% of patients on first-line were using the WHO preferred EFV-based regimen. What are the obstacles to reach the third 90? Of course being far behind the first two nineties is the main issue. Socioeconomic context is not favourable at all, as unemployment is raising in many countries, which implies losing the social security protection. Also housing deficits, malnutrition and cost of surface transportation to the clinics conspire against appropriate and timely periodic visits, and so adherence is at risk. Temporary stock-outs still happen in some countries, with obvious consequences. Last but not least, resistance rates, particularly related to NNRTIs, are as high as 15% in some areas, which highlight the need of obtaining baseline genotypes before first ART start and/or the substitution of efavirenz by drugs with high genetic barrier, like boosted-PIs or dolutegravir.
O143
The 90s in the Americas: retention in care/adherence Carlos Beltran Latin American HIV Workshop Study Group, AIDS, Santiago, Chile According to last numbers released by UNAIDS 18.2 million of 36.7 million HIV infected people are on ART, 1.1 million of them in Latin America. This is far below the two first 90-90-90 goals to achieve 81% of all HIV infected people on ART. Testing and linkage/retention are the main gaps in fighting the epidemic, being both essential to reduce HIV transmission and prevent HIV-related morbidity and mortality. Many factors contribute to poor linkage and poor rates of enrolment in care in Latin America such as patient and sociocultural factors as well as economic and health system barriers. Poor linkage to care after diagnosis has been partially blamed for high rates of late presentation to ART in some countries. Comprehensive services including home-based testing and immediate ART initiation, integration and decentralization of healthcare provision, task shifting to trained health-care workers and lay providers to face up human resource constraints and to provide services outside the office setting and even financial incentives for patients along with social and family support and reduction of stigma and discrimination have been proposed to improve linkage to care. Prompt ART initiation and active and continuing patient education for adherence optimization as well as proactive monitoring of adherence are critical in the setting of treatment as prevention goals and to prevent resistance to ARV drugs. The above-mentioned interventions to promote linkage are also crucial for adherence, along with simplicity and safety of ARV drugs and especially quality and fluency of patient-healthcare provider relationship. Some concerns have been raised recently on adherence of adolescents and young adults who initiated ART in good health and with high CD4 counts. New strategies such as communication technologies and financial incentives may be used to increase adherence in particular settings. Linkage and retention in care require appropriate and trained healthcare teams as well as maintenance of drugs and monitoring tests supply chain. Heterogeneity in availability of this resources and even stock outs episodes are observed in the region. Ending the epidemic in Latin America will take a combination of political will, national policies, strategic planning, resources mobilization and novel, comprehensive and standardized interventions to improve testing, care and treatment.
O144
The 90s in the Americas: prioritization of treatment -is it necessary?
Mauro Schechter Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
In 2014 the UNAIDS launched the 90-90-90 initiative, with a view to help end the AIDS epidemic. Its ambitious goals were that, by 2020, 90% of all people living with HIV would know their serostatus, 90% of all people diagnosed with HIV would be receiving antiretroviral therapy (ART), and 90% of all those on ART would be virally suppressed. Irrespective of the capacity of individual countries to achieve these goals, this initiative provided useful metrics for national programmes to monitor their progress towards universal access to treatment. Optimization of limited and often scarce material and human resources is of paramount importance to achieve the UNAIDS goals. Thus, targeted testing through knowledge of local characteristics of the epidemic and of key affected populations, strengthening of referral systems, identification of patients in more urgent need of care, and improvement of acceptance, adherence and retention in care are some of the issues that need to be addressed in order to achieve the UNAIDS targets.
O211
The second decade: cashing in on evolving capacities for better outcomes Linda-Gail Bekker The Desmond Tutu HIV Centre, Cape Town, South Africa The African continent is currently undergoing a youth bulge. It is estimated that by 2030, one in every four individuals will be African, the vast majority of them under the age of 35 years (You et al., 2014). However, over 40% of all new HIV infections occur amongst youth and 85% of young people living with HIV live in SubSaharan Africa (Idele et al., 2014). Adolescents and young adults are at increased risk of HIV infection due to the many developmental, psychological, social and structural transitions that take place in this period of the life course, yet engaging and retaining adolescents actively in healthcare promotion and provision is challenging in every setting worldwide. Adolescent girls and young women (AGYW) are particularly effected and in South Africa young women are 4-6-fold more likely to be HIV infected than their male counterparts. Huge success in ARV treatment worldwide has allowed more people to live productive lives with HIV and initiation of treatment early has shown to significantly reduce transmission. The Adolescent population, however, struggles to cope with an HIV diagnosis and often gains that are made during paediatric treatment may be lost in adolescence. To tackle the challenges of care and treatment as well as primary and secondary prevention in this critical age group, we desperately need integrated and tailored programmes that are adolescent-friendly and that incorporate biomedical, structural and social interventions. In Latin America, PrEP should be offered to populations with higher HIV prevalence: men who have sex with men (MSM) and transgender women (TGW). The largest gap in the region's HIV care continuum is between those living with HIV and those who are unaware of their status. Therefore, it is expected that a high proportion of MSM and TGW who seek PrEP test positive in the baseline serology. In order to bring these newly diagnosed individuals to virologic suppression a test-and-treat strategy with proper linkage-to-care is necessary. PrEP programmes should collaborate with diagnostic and counselling services and with HIV care facilities. This could impact HIV incidence not only by offering antiretrovirals to high-risk negative individuals but also -and maybe even moreby contributing in diagnosing and linking to care previously undiagnosed HIV-positive individuals (treatment as prevention). Diagnosis algorithm should incorporate new point-of-care technologies capable of identifying acute HIV infections. PrEP programmes should develop specific strategies for hard-to-reach populations and their comorbid behavioural disorders that may interfere with PrEP adherence. Furthermore, linking PrEP users to combination prevention services could reduce the risk of acquiring HIV through counselling, condom distribution, STD diagnosis and treatment services, harm reduction and substance use programmes, mental health services and also through interventions that address socioeconomic and other structural factors that influence HIV transmission. In order to achieve all the potential benefits of PrEP, strong leadership is needed from the public health, behavioural and social sciences fields both in implementation and in research projects.
O314
Treatments for hepatitis C through the Brazilian Unified Health System (SUS)
MoH will have provided 50204 treatments for 12-week and 24-week course of treatment by the end of March 2017. The preliminary analysis of treatment effectiveness in Brazil showed that patients with hepatitis C genotype 1 achieved a cure rate of 97%. Based on results of real life clinical studies demonstrating the low effectiveness of 12-week course of treatment for hepatitis C genotype 3 with cirrhosis, the MoH extended the treatment period for 24 weeks for these patients. Recently, the MoH introduced the 4-drug combination of ombitavir, veruprevir, ritonavir and dasabuvir in SUS. Toward the elimination of hepatitis C as a public health threat by 2030, the Department of STI, HIV/AIDS and Viral Hepatitis in the MoH will submit the revised Guidelines for hepatitis C and coinfections for approval by the National Commission and through public consultation in March 2017.
O323
Efficacy and safety of switching to EVG/COBI/FTC/TAF in virologically suppressed women report the safety and efficacy of subsequent switching to E/C/F/ tenofovir alafenamide (TAF) versus remaining on ATV/r + F/TDF. Methods: After completing the initial randomized, blinded 48-week trial, women on ATV/r + F/TDF were randomized 3:1 to receive open label E/C/F/TAF versus remaining on their current regimen. Viral suppression (HIV-1 RNA <50 and <20 copies [c]/mL) by FDA snapshot analysis, pre-defined bone and renal safety and tolerability endpoints 48 weeks after switch are reported. Women who become pregnant while on study are given the option to continue study drug. Results: 212 HIV-infected, virologically suppressed women were randomized (E/C/F/TAF n = 159, ATV/r + F/TDF n = 53). Virologic suppression (<50 c/mL) was maintained in 94.3% on E/C/F/TAF versus 86.8% on ATV/r + F/TDF (weighted difference: 7.5%; 95% CI: −1.2% to 19.4%), with virologic failure in 1.9%, 3.8%, respectively. More women on E/C/F/TAF achieved <20 c/ mL at W48 compared to ATV/r + F/TDF (84.9% vs 71.7%, weighted difference: 13.2% [−0.0% to 27.5%], p = 0.041). No treatment emergent resistance was detected in either study group. Mean % increase in BMD was higher in the TAF group for both lumbar spine and total hip (Table 1) . Multiple markers of renal safety were improved for participants randomized to TAF (Table 1) . No cases of proximal renal tubulopathy were reported. Participants on TAF had greater increases in lipids (Table 1) , with no difference in TC:HDL ratio (Table 1) . Nineteen women became pregnant during the switch study, 13 E/C/F/TAF and 6 ATV/r + F/TDF and three normal infants have been delivered in each group to date. Conclusions: These data demonstrate that women who switch to an integrase inhibitor + TAF-based regimen maintain high levels of virologic suppression with improvement in BMD and renal function biomarkers, as compared with those remaining on their ritonavir boosted atazanavir + TDF-based regimen.
O324
Significant efficacy and long-term safety difference with TAF-based STR in naïve adults Conclusions: Through W144, participants on E/C/F/TAF had significantly higher rate of virologic suppression (<50 c/mL) than those on E/C/F/TDF, driven by fewer participants on E/ C/F/TAF with no W144 data. Participants on E/C/F/TAF also had significantly higher rate of virologic suppression (<20 c/mL), driven by fewer participants on E/C/F/TAF with viral load ≥20 c/mL. E/C/F/TAF continued to have a statistically superior bone and renal safety profile compared to E/C/F/TDF, Abstract O324- variables, the sum of them gave a numerical value, which made possible the realization of a score and its value varied from 0 to 13 points (Table 1) .
Results: Mean age 38 years/median 39 years. Eighty eight per cent of the patients had CD4 ≤220 cells/μL. Twenty one per cent with HAART at admission to IC. Eighty-seven per cent had an HIV/AIDS history of more than one year. Sixty-one per cent admission for marking disease. Reasons for admission: (1) pulmonary disease 29%: pneumonia (37%), tuberculosis (28%) and pneumocystosis (24%); (2) neurological disease 25%: meningoencephalitis (31%), cryptococcosis (29%) and lesion occupying space (27%); (3) sepsis 20%. Overall mortality 48%. Table 2 shows the number of cases, score obtained (0-13 points), evolution and mortality in each score: the lowest has a better survival rate (90-100%), the highest have a 100% mortality rate. A score of 8 or more points identifies patients at high risk of adverse prognosis, with a sensitivity of 80%, specificity of 78% and positive predictive value of 77% and negative of 80%. A significant association was found between score and mortality. The receiver operating characteristic (ROC) curve shows the cut off point for this score, where it achieves the highest sensitivity and specificity (8 points). The area under the curve has an acceptable discrimination value (0.8664711 (0.8366941-0.8962480)) ( Figure 1 ). Conclusions: Admission of an HIV/AIDS patient to IC should be made taking into account several prognostic factors and not on an isolated basis. We believe that the achievement of a score does not replace clinical judgment at all in conjunction with the patient's decision. The prognostic score presented is easy to perform using accessible variables and has utility to identify patients at high risk of death. We encourage your use.
CO-MORBIDITIES AND COMPLICATIONS OF DISEASE AND/OR TREATMENT

P004
Clinical characteristics and long-term monitoring of a cohort of HIV/AIDS patients admitted in intensive care Conclusions: Our case series provides evidence that the severity of the acute event influences mortality, and are also statistically significant other variables such as the HIV/AIDS stage and the pathology that determined its entry. Intra-IC mortality was higher than the literature. In the long-term follow-up, variables such as nutritional status, immunological status and HAART have significance, mentioned in different publications [3, 4] . The low mortality at three years of follow-up, shows as a chronic disease, influenced by the presence of HAART (p significant).
P005
Prevalence of hepatitis B, hepatitis C, syphilis and tuberculosis in a large cohort of patients living with HIV/ AIDS in Colombia Introduction: The HIV Colombian group (VIHCOL) comprises 17 HIV care centres located in 10 Colombian cities, which provide outpatient medical care to people living with HIV/AIDS. In this current study, we aimed to determine the prevalence of co-infection of hepatitis B, hepatitis C, syphilis and tuberculosis amongst a large cohort of HIV-positive patients in Colombia. Methods: We conducted a multicentre retrospective study between January 2014 and December 2015 in 17 HIV care centres located in 10 Colombian cities. HIV-infected patients over 15 years of age receiving medical care in the participating institutions were included. Prevalence rates for HBV (either HBsAg, anti-HBs or anti-HBc), HCV (anti-HCV), syphilis (non-treponemal and treponemal tests) and latent tuberculosis (TST ≥5 mm) were obtained and analysed by age, sex and health system affiliation. History of active tuberculosis was also recorded. Results: A total of 22,492 HIV-positive patients were included during the study period. Prevalence rates of co-infection with HBV (HBsAg), HCV, latent tuberculosis and active tuberculosis were 10.2% (95% CI: 9.5-11%), 0.8% (95% CI: 0.6-1%), 12.4% (95% CI: 12.2-14%) and 2.1%, respectively. Non-treponemal test was positive in 12.3% (95% CI: 11.6-13%) of the patients while treponemal test was positive in 18.2% (17.1-19%) of the patients. HBV infection was more frequent in HIV patients belonging to the contributory plan than in the subsidized and special plans (13% vs 2.5% vs 2.3%). Subsidized patients had higher syphilis co-infection rates (22.3% based on non-treponemal tests or 33.8% based on treponemal tests) when compared to the other health plans. Missing data varied for the different laboratory markers, being up to 51% in some instances. Conclusions: Hepatitis B co-infection rate was high, while hepatitis C co-infection rate was lower compared to general population. We found statistically significant differences between health system affiliation plans for hepatitis B, syphilis and latent TB. Introduction: The adherence to highly active antiretroviral therapy (HAART) remains a challenge in the treatment of HIV patients, even with current simplified treatments. Recent publications indicate that factors such as depression, stigma, unemployment, poverty, side effects to the drugs and limited access to treatment, are the most commonly related to poor adherence. However, symptoms like fatigue, cognitive failure and sleep disorders should also be considered as variables related to low compliance. Therefore, we Abstract P006- Table 1 investigated the frequency of symptoms associated with depression, self-reported psychosocial and treatment-related factors, in a sample of patients with failure to the first line of HAART [1] [2] [3] [4] . Methods: A descriptive, cross-sectional study, with a non-probabilistic sample of 50 patients. Patients were evaluated by the mental health department after the documentation of virological failure. All patients were evaluated using the Beck Depression Inventory second edition (BDI-II) and Medical Outcomes Study Short Form-36 (SF-36). Using the World Health Organization suggested criteria, we asked the patients to self-report the adverse effects of the treatment that resulted in low adherence and also to report stressful life events that took place during the three months prior to the time of the evaluation (Tables 1 and 2 ) [5] .
Results: Of the all participants (85% men), 86% had emtricitabine/ tenofovir disoproxil fumarate/efavirenz [line antiretroviral therapy 1 (LAT1)] and 14% had emtricitabine/tenofovir disoproxil fumarate/ atazanavir/ritonavir (LAT2). No significant differences in sociodemographic and HIV-related variables were seen. Patients in LAT1 reported a higher frequency of fatigue, changes of sleep pattern and functionality impairment (t = 2.221-3.834, p < 0.01). On the self-report questions patients on LAT2 had more gastrointestinal complaints, whereas sleep disturbance, irritability and slowing down, were present only in the LAT1 group (Chi-square = 3.324, DF = 9, p < 0.05). Participants in group 2 reported higher frequency of stressful life events (Chi-square = 1.115, DF = 5, p < 0.05).
Conclusions:
In this study, we showed that participants in LAT1 had a higher frequency of neuropsychiatric symptoms that could be related to sleep deprivation secondary to treatment use, in comparison with LAT2. This evidence suggests the importance of periodic assessment of mental health of patients initiating HAART and monitoring side effects to antiretrovirals. This would ultimately reduce the number of treatment failures and may help to develop of interventions that facilitate reinsertion to daily activities. Introduction: Historically treatment of HIV and HCV co-infection has always been a concern due to the poorer response to anti-HCV therapy compared to mono-infected and to the worsened fibrosis progression in the presence of HIV. Currently Brazil includes HIV co-infection for treatment regardless of the degree of hepatic fibrosis and prioritizes these patients to receive a treatment regimen compatible with their antiretroviral therapy. The DAAs allow co-infected to be treated like HCV mono-infected patients, calling into question whether these patients should be considered a special population any longer. Clinical and epidemiological profile as well as response evaluation to treatment of hepatitis C/HIV coinfected patients are described in this article.
HIV-HEPATITIS CO-INFECTION P007
Methods:
We enrolled all co-infected patients under treatment from December 2015 to June 2016 at a co-infection clinic at Hospital das Clínicas of the State University of Campinas-São Paulo. The patients received sofosbuvir + daclatasvir with or without ribavirin, after antiretrovirals interactions were managed. Demographic, clinical and laboratory parameters were retrospectively analysed in medical records.
Results: 50 patients were enrolled, GT1a (66%), GT1b (16%), GT3 (8.3%), GT4(2%). 88% were male and 74% were white. The mean age was 49,6, mean baseline HCV RNA was 6.3 log10 UI/mL, mean baseline CD4 was 704 cells/μL, 66% were classified as C3. 56% had cirrhosis, 41% underwent ARV switch. There were three patients who did not follow-up, one because of reclusion, another one because of collateral effects of the new ARV prescribed. As a partial result, we obtained 76% of SVR4 and 62% of SVR12, while eight patients are still completing SVR with non-detectable PCR Abstract P006- Introduction: The geographic distribution of hepatitis C in Latin America reveals that the most common genotypes are type 1A and 1B [1] [2] [3] . However, there has been a change in the dynamics of the prevalence of hepatitis C virus types in our HIV programme care. The aim of this study is to determine the characterisation of HIV/ hepatitis C co-infection. Methods: A cross-sectional retrospective study was developed in the CEPAIN HIV programme care at Bogota, Colombia. All patients were tested for hepatitis C, since January 2010-December 2016. The reactive cases were identified due to the presence of antibodies against the hepatitis C virus (Anti-HC). The clinical history of each patient was reviewed to extract the clinical variables, in these patients the presence of viral RNA was investigated; Positive cases were considered as active HCV infection.
Results: Of the 4233 HIV patients, it was diagnosed 35 patients with hepatitis C. The average age is 37 years, with a greater presentation in the age group of 35-49 years (48.2%). The distribution according to the patients`gender showed that the majority were men (34 people). In 2016, the prevalence of hepatitis C genotype 4 in the study population was 0.51 per 100 people. Table 1 shows cases and prevalence rate of genotype 4 over the seven-year period. Conclusions: It is observed that contrary to the epidemiology in the region for hepatitis C genotype 4, there is a significant increase in cases, which implies a different therapeutic approach with the advent of new therapies. Molecules as sofosbuvir, has not an adecuate entry or import to the country, which makes it difficult to achieve and treat the patients. Of the 22 patients only 4 have been used interferon treatments, the rest are waiting for adequate, effective and non-toxic drugs.
P009
GT3 treatment in a real-life setting Introduction: Hepatitis B virus (HBV), hepatitis C virus (HCV) and HIV infections share transmission routes. Higher morbidity and mortality are seen in HBV/HIV and HCV/HIV co-infected patients compared to patients with a viral hepatitis-or HIV-monoinfection. Viral hepatitis treatment in HIV-infected patients is therefore imperative. Suriname, a South American middle-income country, has an estimated 1.0% HIV prevalence rate, but the HIV/hepatitis co-infection rate is unknown. In this study we investigated the viral hepatitis co-infection prevalence in people living with HIV/AIDS (PLWHA) attending the Academic Hospital Paramaribo (AZP), the largest HIV clinic in Suriname. Methods: Retrospective data were obtained from all PLWHA that attended the AZP from 1 January 2008 to 31 October 2016. Sex, age, HBV and HCV testing results were collected. Characteristics associated with chronic HBV (positive Hepatitis B Surface Antigen (HBsAg)) and/or anti-HCV were examined using descriptive statistics and logistic regression analysis. Results: Over half of the 1929 PLWHA enrolled at the AZP were female (53.2%) and had a median age of 40.8 (33.4-50.2), 37.9% were lost to follow-up (had not attended the clinic for over a year) and 4.2% were deceased. Testing rates were 66.0% and 61.2% for HBV and HCV respectively. 6.4% of those tested were HBsAg positive (82/1273; 95% CI 5.2-7.9), 1.4% were HCV positive (17/1181; 95%CI 0.9-2.3). 0.3% tested positive for HBsAg and HCV (3/1166; 95%CI: 0.1-0.8). Age above 40 was associated with anti-HCV (OR = 4.6; 95%CI: 1.3-16.1, compared to PLWHA younger than 40), other determinants were not significantly associated with HBV and HCV co-infection. Conclusions: 6.4% of Surinamese PLWHA are co-infected with viral hepatitis B and 1.4% with hepatitis C, which is higher than the HBsAg and anti-HCV prevalence (2.9% and 1.0%, respectively) in the general emergency department population. This highlights the need to test all HIV infected patients for viral hepatitis and offer treatment for those infected. Regarding HCV, implementation of Direct Acting Antiviral Therapy is therefore highly recommended. Furthermore, we noted a high lossto-follow-up rate and interventions are needed to improve retention in care. Introduction: Approximately 10% of the HIV-infected population worldwide is infected with hepatitis B virus (HBV) [1] . HIV increases the risk of cirrhosis and end-stage liver disease in HBV co-infection. In Central America, the adult hepatitis B prevalence rate is below 2% [2] . Absent data on Honduras, HBV prevalence rates in El Salvador and Guatemala, Honduras' neighbours, are 1.0 and 0.5, respectively [3] . The rate for people co-infected with HIV and HBV is unknown. Siempre Unidos, the only non-governmental organisation authorized by Honduras' government to provide antiretroviral medications, operates two clinics providing HIV education, testing and treatment.
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Patients are primarily of low income and educational levels and live in urban or semi-rural settings. Our aim was to test our HIV patients for hepatitis B and assure treatment for all who were co-infected. Figure 1 ) and most of the cases were in men (62.6%). Heterosexual exposure amongst elder men (73.4%) was predominant when compared to the general population (51.2%). Most of the cases amongst the elderly (50.4%) was amongst whites, while in the general population we verified a higher proportion of cases (50.1%) amongst blacks. The proportion of HIV/AIDS cases in illiterate senior citizens was 6.9%, while in the general population it was 2.9%. The majority of them started ART with CD4 <200 (Table 1) . According to data from the PCAP 2013 [1] , the proportion of illiteracy (or low schooling) amongst the elderly may lead to late diagnosis, which corroborates the finding that a greater proportion of elderly individuals have a late ART initiation, with CD4 <200. Despite this, we observed an increasing distribution of ARV for individuals over 50 years, indicating that this population has a good adherence to ART.
Conclusions:
The aging process involves complex issues regarding sexuality that influences the vulnerability of elder people. In the light of increased AIDS detection rates found amongst this population, it is important to expand access to information regarding HIV/ AIDS prevention, and also to encourage the dialogue about sexuality and sexual health problems people aged 50 and over may Abstract P012- There is no solid data on the best ART switch strategy in these patients. Our objective was to describe the ART switch recommended by a national peer-advisory board (CORESAR) to practitioners caring for HIV-TB co-infected patients, to investigate the determinants of the choice of the switch modality and to assess the virologic outcomes of the diverse switch strategies. Methods: We conducted a nationwide, HIV clinic-based, cohort study in Mexico. Inclusion criteria were: adults under ART with newly diagnosed TB and requiring the start of anti-TB, whose physician had received therapeutic advice, by a panel of experts, regarding the switch of ART to minimize pharmacologic interactions. The primary end-point was the incidence of HIV viremia control (persistent plasma HIV-RNA levels of <200 copies/mL) during anti-TB. Noncompleters were considered as therapeutic failure. Results: Fifty-six patients were assessed. ART regimens at TB diagnosis were: 2 NRTI + PI (32 patients), 2 NRTI + NNRTI (20 patients) and other regimen (4 patients). Twenty-two patients were switched to 2 NRTI + raltegravir (RAL); 18 patients, to 4 NRTIs; 8 patients, to 2 NRTIs + lopinavir/ritonavir 400/400 mg (LPV/r+) bid; 5 patients, to 2 NRTI + NNRTI; and 3 patients, to a single NRTI (3TC or FTC). Patients switched to RAL (or to NN) had fewer prior failed ART regimens, more often had viral control and less frequently had a PI-containing scheme, at switching. Rate of patients maintaining viral control during anti-TB was 68%, 0%, 37% and 100% amongst those receiving RAL, 4 NRTI, LPV/r+, NRTI and NN, respectively. Half of patients achieving viral control with RAL had viral failure at switching. Conclusions: In patients already receiving ART and initiating anti-TB a switch to RAL (or to NN) may be an adequate strategy, particularly amongst those with favourable viral control history. Conversely, contention with only NRTI could be an acceptable alternative for drugheavily exposed individuals. Our results ought to be interpreted with caution as they were generated through an observational survey.
Abstract P014- Figure 2 . HIV/TB co-infections.
Abstract P014- Figure 3 . CD4 count at Diagnosis.
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A local audit of the standard for diagnosing latent tuberculosis infection for adults living with HIV in a tertiary hospital in Santiago, Chile Introduction: Tuberculosis (TB) remains a public health concern around the world; approximately 10% of people living with HIV with latent TB infection (LTBI) will develop active TB disease each year. There are currently two tests for diagnosing LTBI, TST (tuberculin skin test) and IGRA (interferon-gamma release assay), but TST remains the most preferred method for LTBI diagnosis in resource-limited countries. According to the Chilean national guidelines, all those living with HIV should have access to LTBI investigation through TST. Our audit aimed to assess whether the standard for diagnosing LTBI for adults living with HIV is being implemented in clinical practice in our centre to highlight gaps in service delivery. 
Conclusions:
The standard for diagnosing LTBI has improved over the period, but up to 20% of the patients do not attend their scheduled test for LTBI. Data on the prevalence of latent TB by TST in our HIV clinic is similar to the prevalence described in Chile using the same TST. In addition, an important proportion of patients do not follow up the second visit to obtain their results. For this reason, it would be convenient to screen for LTBI using IGRAs, which require only a single visit and do not cause a false-positive reaction, but the limitation is the cost.
HIV and women including MTCT
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Efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/ 3TC) fixed dose combination (FDC) compared with ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatmentnaïve women with HIV-1 infection (ARIA study): subgroup analyses Introduction: Built around an unboosted integrase-strand transfer inhibitor (INSTI), the FDC of DTG/ABC/3TC offers a complete regimen for treatment of HIV-1 infection, with good tolerability and a high barrier to resistance. To gain additional data for women on this regimen, we conducted ARIA, an international, randomized, open-label study to evaluate the safety and efficacy of DTG/ABC/3TC versus ATV/r + FTC/TDF (ClinicalTrials.gov: NCT01910402). Methods: Treatment-naïve adult women, with HIV-1 RNA ≥500 copies(c)/mL were randomized 1:1 to 48 weeks of treatment with DTG/ABC/3TC or ATV/r + FTC/TDF once daily. The primary endpoint was the proportion of women achieving an HIV-1 RNA <50 c/mL at week 48 (Snapshot algorithm). Women who became pregnant were withdrawn, and were possible offered entry into a DTG/ABC/3TC pregnancy study. Additional analyses were performed to evaluate efficacy based on geographic region and baseline characteristics. Results: 495 women were randomized and treated. Subjects were well matched for demographic and baseline characteristics. Median age was 37 years; 45% of subjects were White and 42% Abstract P017- Table 1 (1990-2015) , of which 18,179 (13.5%) were women. The mortality rate in women had a growing trend between 1990 and 2009 when it reached 1.69 deaths per 100,000 inhabitants. After 2009, the rate decreased by 12% to reach 1.47 deaths per 100,000 inhabitants by 2015 (Figure 1) . However, there are significant differences in the distribution of mortality in the regions of the country. In 2015, the Mexican States of Veracruz (4.14 per 100,000 women), Colima 
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Gender differences in risk factors and clinical outcomes of patients receiving antiretroviral therapy at an HIV clinic in Guatemala City over a 9-year period Theresa Tharakan and Matthew Anderson Family and Social Medicine, Albert Einstein College of Medicine, Bronx, NY, USA Introduction: There is no consensus on gender differences in clinical outcomes of HIV-infected patients. Immunologic, virologic and survival data for patients receiving antiretroviral therapy (ART) show an inconsistent presence and direction of a gender gap. Gender and sexual behaviour-based outcomes analysis is lacking in Guatemala, which has largely sexual transmission of HIV. We examine outcomes of HIV-positive Guatemalans receiving ART over a 9-year period. Methods: Retrospective cohort analysis was conducted using a database of treatment-naïve patients offered free ART at the Clinica Familiar Luis Angel Garcia in Guatemala City from 2004 to 2014. Multivariate Cox regression was used to study gender differences in all-cause mortality, immunologic failure (CD4 <100 cells/μL twice or CD4 <baseline) and virologic suppression (viral load <50 HIV-1 RNA copies⁄mL within one year of starting ART). Results: 4248 patients were included: 2605 men, 1617 women and 26 transgender patients (analysed separately). Compared to men, women had higher median CD4 counts (198 vs 126 cells/μL, p < 0.001) and lower median viral loads (6.48 × 104 copies/mL vs 11.27 × 104 copies/mL, p < 0.001) at baseline. KM analysis demonstrated a relationship between gender and survival after initiating ART (Figure 1) The viral RNA was isolated from 28 pregnant women with elevated VL and used as target to amplify the protease and reverse transcriptase regions of the HIV-1 pol gene. PCR products were sequenced and the generated data used to determine the subtype and resistance of HIV-1 to ARV according to HIVdb v6.1.1. Results: Between three and five months after initiation of HAART, 50% of pregnant women had undetectable VL, 12.2% had values between 100 and 1000 copies/mL and 37.8% pregnant women above 1000 copies/mL. The predominant viral variants in the group of pregnant women who were assigned the HIV-1 resistance profile to antiretrovirals were subtype B (21.4%) and CRF20, 23, 24_BG (17.9%). The 17.8% (5/28) had any mutation associated with ARV resistance; 7.1% (2/28) to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors (NNRTI) combinations; 3.6% (1/ 28) to the NNRTI and 7.1% (2/28) to the protease inhibitors. The antiretroviral drugs with high resistance were 3TC, AZT, NVP and EFV. Conclusions: The systematic monitoring of the virological response in HIV-positive pregnant women allowed the optimization of HAART and contributed to the sustainability of the prevention of mother-to-child transmission of HIV.
HIV AND VULNERABLE POPULATIONS
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Switching from TDF to TAF in HIV-infected adults with low BMD: a pooled analysis Introduction: Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) represent an important treatment strategy to improve bone health in HIV-infected individuals with low bone mineral density (BMD), but this has not been specifically investigated.
Methods: This analysis consisted of pooled data from two prospective phase 3 studies (studies 109 and 112) of HIV suppressed adults on a TDF-based regimen switching to elvitegravir, cobicistat and emtricitabine (E/C/F) co-formulated with TAF. In adults with clinically significant low BMD by dual energy X-ray absorptiometry (Tscore ≤ −2.0 at the lumbar spine, femoral neck, or total hip) at baseline (BL), we assessed percentage change in BMD and T-score at the lumbar spine and total hip and change in proportion with osteoporosis (T-score ≤−2.5 at any site) at weeks (W) 96. Logistic regression was used to determine BL predictors of a clinically significant improvement (≥ 5% increase) in lumbar spine and total hip BMD, adjusted for age, race, sex and BL BMD. Results: Of the 1117 enrolled who switched from TDF to TAF, 214 (19%) had clinically significant low BMD at BL (median age 46 years, 85% male, 63% White, 26% smokers) with 43% (93/ 214) osteoporosis. The BL median (interquartile range: Q1, Q3) T-score (lowest of any 3 sites) was −2.4 (−2.8, −2.2). At the spine, the median (Q1, Q3) % BMD change at W96 was 2.53% (0.22%, 5.31%) and T-score change was 0.19 (0.02, 0.42) (p < 0.001). At total hip, BMD change at W96 was 2.39% (0.72%, 4.18%) and T-score change was 0.14 (0.04, 0.24) (all p < 0.001). Of the 86 with BL osteoporosis and W96 BMD data, 23% no longer met criteria for osteoporosis at W96. Of 214 with low BMD, 24% and 15% had a clinically significant BMD increase at the spine and total hip, respectively. In multivariable analysis, BL factors associated with clinically significant BMD increase at W96 were higher fraction excretion of phosphate (FEPO4 ≥ 10%) for the hip and higher BMI (≥30 kg/m 2 ) and procollagen type 1 N-terminal propeptide (P1NP >1.85 log10 ng/mL) levels for spine. Conclusions: HIV-infected individuals with clinically significant low BMD on a TDF-based regimen who switched to E/C/F/TAF experience a~2.5% BMD increase over 96 weeks and a reversion from osteoporosis in approximately 1/4 of patients. Baseline urinary phosphate wasting and high bone turnover may identify TDF-treated HIV-infected patients with low BMD who may benefit the most from a switch to TAF. Introduction: Transgender women (TGW) are a vulnerable group for HIV infection and are 34-49 times more likely to be infected than the general population. Furthermore they receive little to no care at health services which makes it difficult for them to receive an early or timely diagnosis [1, 2] . It is estimated that TGW with HIV have higher ART treatment failure rates than other groups due to poor adherence. HIV prevalence in TGW is approximately 19.1% globally [3] , even though there are very few studies published. A few studies report that 77% of TGW with HIV receive medical care, only 65% receive ART and 44% have an undetectable viral load [4] Conclusions: HIV prevalence in TGW that receive care in our clinic is much higher than the reported in the international literature since the Center for Transgender Services is located inside the HIV clinic. Unfortunately not all patients agree to HIV testing thus it is not possible to diagnose everyone. Is probable that the retention and virologic suppression in our patients id higher compared to other provides due to the fact that the hormone therapy services may very well be an incentive for controlling the HIV epidemic in this population group. Introduction: The Caribbean region still represents the higher incidence on HIV and other STIs infections in the western hemisphere [1] . HIV transmission in the Dominican Republic appears to be concentrated amongst key populations, especially transgender women [2, 3] . The objective of this study was to evaluate the prevalence of HIV, syphilis, hepatitis B and hepatitis C infections amongst transgender women in the Dominican Republic. Methods: From the PEPFAR's prioritized provinces for the HIV response we selected six provinces in the Dominican Republic to conduct a survey and blood sampling in Transgender women population. We used a respondent-driven sampling methodology to identify hard-to-reach populations [4] . After informed consent Abstract P022- Figure 1 . Continuum of care for HIV-infected TGW receiving care at CSC.
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we collected peripheral blood samples for HIV, syphilis, hepatitis B and C. Results: A total of 311 samples and epidemiological data were collected. Compared with the general population (−1%) the HIV frequency in trans-populations was 17.8-38.5%; syphilis was 23.5-55.5%; hepatitis B was 1.6-5.8%; and for hepatitis C was 0.03-3.8% (Figure 1 ) Early sexual intercourse, risk behaviours and violence were detected in higher levels. Conclusions: Despite many efforts in the fight against HIV, disparities in STIs frequencies are still observed amongst trans-populations. This is influenced by a poor access to formal employment, illiteracy, lower access to health services and provision of population-specific services. Integrated services and comprehensive care for trans-populations will impact the reduction of HIV/STIs infections.
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Analysis of a large Colombian cohort of HIV-infected patients over 50 years of age during 2013-2015 Methods: We conducted a multicentre retrospective study between 2013 and 2015 in 17 HIV care centres from 10 Colombian cities. HIV-infected patients over 15 years of age receiving medical care in the participating institutions were included. We compared two patient groups: those ≥50 yo and those 15-49 yo, in terms of immune status at admission, first antiretroviral treatment (fART) and virologic success (viral load <50 copies/mL) at one year. Results: A total of 128 (11.5%), 251 (14.4%) and 372 (13.4%) patients ≥50 yo were diagnosed with HIV in 2013, 2014 and 2015, respectively. The proportion of patients ≥50 yo with a baseline CD4 count <200 and <350 cells/µL were 32.8% and 63.3% in 2013‚ 42.2% and 63.7% in 2014 and 36% and 59.7% in 2015, respectively. Frequency of EFV as part of fART in patients ≥50 yo progressively increased: 45.5% in 2013, 60.2% in 2014 and 69.6% in 2015. ZDV/3TC was the most frequent NRTI-based combination ART in 2013 (36.4%) and 2015 (57.5%), in contrast to TDF/XTC in 2014 (39.1%). Virologic success rates for patients ≥50 yo on ART were 80.5%‚ 80.2% and 80.4% in each study year, respectively (p < 0.001 when compared to patients <50 yo) In contrast to patients <50 yo, patients ≥50 yo had more frequently a late immune presentation but achieved a significantly higher virologic suppression (p < 0.05). Conclusions: HIV diagnosis and access to ART occurred later in HIV population ≥50 yo, but this patient group had a better treatment response. Strategies for an early identification of this age group are encouraged. Introduction: Brazil has the fourth biggest penitentiary population in the world, with an average occupation rate of 161% at the facilities. The registered growth in the period of 2000-2014 was on average 7% per year, an amount 10 times bigger than the Brazilian population growth, 94% of the quota being male [1, 2] . Populations deprived of freedom are considered high-risk for sexually transmitted diseases, due to the favourable conditions encountered in prison for the propagation of diseases [3, 4] .The State of Paraná presents the fifth biggest jail population in Brazil accounting for 4.61% of that population and has tried over the years to develop health attention policies to the convicted within the National Health Plan at the Penitentiary System (PNSSP) [5] . The main goal of this study was to estimate the predominance of HIV markers within the male jail population at the prison system in the State of Paraná. Methods: Cross-sectional epidemiologic survey for HIV infection held in nine male prisons in Paraná in the period of May 2015 to December 2016. The State of Paraná presents 23 closed system male correctional facilities, with a jail population of 16,657 men incarcerated in closed system. The stages of the investigation included counselling, information about intervention, orientation about sexually transmitted infections, informed consent for the data gathering and blood sampling for the HIV test performed in a certified laboratory. The ELISA test was used as a criteria for HIV with the confirmation through a positive Western Blot test. The data analysis was based in the predominance with confidence intervals estimates. Results: In total, 1192 men were addressed, 1133 (95%) were subjected to a diagnosis for the HIV test. The estimated predominance of the infection by HIV from this evaluation onwards was of Conclusions: Infectious and contagious diseases tracking and investigation in the penitentiary system that promote knowledge, contribute directly to the adoption of effective disease control measures, for diseases such as HIV, in the freedom deprived population, as well as the feasibility maintenance of an egress individual able to work and socially capable of integrating himself in society.
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P026 Prevalence of HIV infections between incarcerated men in
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Correlation between optimal hormonal therapy and viral load amongst transgender women with HIV infection Introduction: The pooled HIV prevalence was 19.1% in 11,066 transgender women (TGW) worldwide [1] . It is known as the suboptimal adherence of ART in this group [2] . TWG have lower percentage of ART adherence compared to non-transgender men (78.4% vs 87.4%) and viral suppression (50.8% vs 61.4%). Optimal HT adherence is associated with adherence to ART [3] . Objective: Correlation of the viral load amongst HIV-positive TGW on ART with optimal HT or TWG on ART without HT. Methods: The information was taken from the clinic data base and the SALVAR database. The viral load and serum hormones were taken before HT and last visit at least three year after initiating HT. Adequate HT is evaluated by serum hormonal concentrations (E2 = 50-200 pg/mL, total testosterone <0.5 ng/mL). In our protocol, the viral load must be undetectable (<40 copies) before HT they were classified in groups for E2 serum concentrations (>200, 200-50 and <50 pg/mL) and for testosterone serum concentrations (>0.5 and <0.5 ng/mL). Results: A total of 272 TGW with ART, 60.6% of TGW (n = 165) with HT and 39.4% (n = 107) without HT. Of the TGW with hormonal therapy 90.9% (n = 150) have undetectable viral load and 10.1% (n = 15) have detectable viral load. 103 TWG without HT were consider for analysis 4 TGW were excluded. TGW without HT 66% (n = 68) have undetectable viral load and 34% (n = 35) detectable viral load. Of the Group with HT 85 patients had hormonal serum concentrations, 93% (n = 79) have undetectable viral loads and 7% (n = 6) have detectable viral load. 45.56% TWG (n = 36) had optimal HT (E2 50-200 pg/mL) 5.06% (n = 4) were above optimal treatment and 49.36% (n = 39) were below optimal treatment. The testosterone concentrations 69.4% (n = 59) were on optimal hormone concentrations (0.5 ng/mL). Conclusions: Viral loads are undetectable on the 90.9% TGW on TH versus 66% without HT, in our clinic the HT is free of charge with endocrinologists, this can be encouragement for optimal adherence of ART. The majority E2 concentrations 49.36% were below optimal treatment and testosterone serum 30.5% were suboptimal. This can be explained that in part of previous year the clinic did not have supply of HT. Just 5% were overmedicated. The Attention model of our clinic can be an example of positive influence of incentives on TGW for optimal adherence.
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Reducing HIV risk behaviour after intervention with young leaders of key populations: an experimental analysis Diego Agostinho Calixto Department of STI, HIV/AIDS and Viral Hepatitis, Ministry of Health, Brasília, Brazil Introduction: Peer dialogues influence the adoption of behavioural changes to reduce the risk of HIV infection. By intervening experimentally in the community to change risk behaviour patterns, it may be possible to promote widespread reductions in HIV risk practices within a population [1] . Methods: The intervention identified and trained young age range 18-26 people who are reliably identified as leaders amongst one of these key populations -gay men and MSM, transgender people (transvestites and transsexual women), drug users and harm reducers and sex workers -in all five regions of Brazil to act as multipliers of behavioural changes for their peers, in relation to HIV. We also include young people living with HIV, considering that it is important that these young people share the experience of living with HIV with other young people in greater vulnerability and risk [2] . Results: 140 young people from the key populations were trained in the 5 Brazilian regions. The proportions of the key populations trained in this intervention were 41.9% homosexuals and MSM, 14.5% harm reduction or drug users, 8% transgender people, 6% sex workers and 15% young people living with HIV. Approximately 70% of young trained in this intervention have already developed some activity to multiply the information about prevention and behavioural practices to reduce HIV infection in their respective territories and communities, promoting knowledge about combination prevention and changes related to sexual practices and behaviours. Conclusions: Interventions that empower young to endorse change can produce or accelerate changes in the behaviour and sexual practices of the young population to reduce the risk of HIV infection. These interventions have developed a network of multipliers in a successive chain of HIV information and combination prevention to reduce HIV Introduction: Retention in care plays a critical role in achieving viral suppression and has a recognized impact on public health. Men who have sex with men (MSM) and transgender women are key vulnerable populations, however, recent research suggest they constitute a minority of HIV-infected adults in care. We aimed to examine the proportion and factors associated with retention in care in MSM and transgender women newly diagnosed with HIV. Methods: We performed a retrospective study including all adult patients (≥18 years) self-identified as MSM or transgender with a new HIV diagnosis from 2002 to 2014 in a public hospital in Buenos Aires. We evaluated demographic characteristics, immunological status at diagnosis and proportion of linkage and retention in care for both groups. Individuals who visited at least once a healthcare professional for HIV after diagnosis were considered to be linked. Retention in care was defined as two or more visits separated for ≥90 days in the first year after diagnosis. Logistic regression was used to identify factors associated with retention in care. Results: A total of 1239 patients were tested positive for HIV during the study period, of whom 314 (25.34%) were self-identified as MSM and 108 (8.71%) as transgender women. Compared with MSM, transgender patients had similar CD4+ counts at diagnosis (364 vs 386 cells/μL) and years of education (10 vs 12 years). Only a minority of subjects (4.5% of transgender women and 17% of MSM) had social insurance. A high proportion of MSM and transgender individuals were linked within three months of diagnosis (94.8% vs 95.2%), however only 40.3% of transgender and 61% of MSM met the retention criteria. The odds of being retained in care were higher for MSM than for transgender patients [OR 2.3; (CI 95%: 1.83-3.20)]. Cocaine abuse, CD4+ cell count at diagnosis, years of education, social insurance, country of origin (Argentina vs others) and place of residence (Buenos Aires city vs others) were not associated with retention in care in this cohort. Conclusions: Our results suggest that there is a need to improve interventions to retain both of these key populations in care with special emphasis on transgender patients. . Amongst the positive cases, 85% were tested for HIV for the first time. Although the prevalence was higher in men than women, the difference was not significant (3.56% vs 2.31%, p = 0.14). No significant differences were found in relation to age. In men who had sex with men, the prevalence was 11.8% (95% CI: 4.7-26.2), showing a significantly greater probability of a positive result with an OR: 5.37 (95% CI: 1.46-16.35; p = 0.01).
Conclusions:
The HIV prevalence observed in this population was seven times higher than the prevalence reported for the general population of Panama. Cultural or vulnerability issues could explain this finding, and a study assessing these factors should be carried out in order to establish risk reduction strategies in the Ngäbe Buglé population. Criteria for inclusion: all HIV infected prisoners who were receiving medical care at our Infectious Diseases Unit during December 2016 were included in the final analysis. During 2016 several strategies were implemented in order to meet WHO 90-90-90 goals: voluntary HIV testing was offered to inmates when they entered the prison, HAART treatment was initiated at first visit with the ID specialist, every HIV inmate was evaluated at least once a month, local HIV treatment guidelines were followed. Data were obtained from an electronic database of medical records. All statistical analysis was undertaken using Statistics SPSS. Results: On 31 December 2016, a total of 62 HIV positive inmates remained incarcerated (>90% of the total estimated cases in this federal prison): 100% male. Median age: 37 (min 21-max 74). Average CD4 count of 427 cell/mL (min 59-max 1120). Eighteen out of 62 inmates (29.03%) were co-infected with hepatitis C, and a total of 5 inmates (8.06%) had TB in the past. Sixty-two inmates (100%) were linked and retained to healthcare, 61 inmates (98.38%) received HAART. There were 48 inmates with more than four months of HAART; amongst them, 43 had viral loads results. 40 (93%) were under virology control with a viral load of <200 copies/mm 3 Conclusions: Chilean women behave similar to other Latin American ones: they access to treatment with very advanced disease, the reasons for testing are an HIV positive partner, due to illness detected in health centres, or during pregnancy. We could observe that Mapuche women are diagnosed later, and they access to care with very advanced disease compared to non-Mapuche. The level of education is independent of admission with very advanced disease. Mapuche housewives, with HIV negative partners, access to care with more advanced disease than those not Mapuche. Finally, we point out that Mapuche women are more vulnerable, which requires a culturally relevant health approach.
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High HIV prevalence in non-high risk groups in urban Honduras (Table 1) . As shown in Figure 1 , more than 20% of gay, MSM, transgender and transsexual participants reported to not feel embarrassed to take PrEP. While less than 5% of all the participants reported to feel really embarrassed to take PrEP. As shown in Figure 2 , 40% of the providers reported that they might prescribe PrEP if the patient demonstrates HIV risk, while 4% reported they would not prescribe PrEP at all. Conclusions and future directions: Negative stigma was not tied to the use of PrEP, meaning potential users would welcome the implementation of PrEP. Despite the small sample size of healthcare providers (n = 25), more than half would consider prescribing PrEP if a patient demonstrates high HIV risk. Gain in-depth perception of the healthcare providers' perception of PrEP. Interview other minority populations, such as Haitian immigrants or HIV+ individuals.
MODELS OF CARE/SCALE UP OF TREATMENT
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Reducing the gap: a strategy to strengthen the specialized HIV care clinics to improve detection and linkage to care Abstract P034- Figure 2 . The likelihood of a healthcare provider to prescribe PrEP if the patient demonstrates a high risk for HIV.
Dirección General, National Center for Control and Prevention of HIV and AIDS, México City, Mexico
Introduction: It is estimated that 200,000 people live with HIV in México, but only 63% know their diagnosis [1] . The lack of universal detection is one of the main barriers to access to care. This article describes a strategy which objective was to strengthen specialized HIV units to contribute to reduce the diagnostic gap, ensure the linkage of people with HIV to health services as their incorporation into ART. Methods: Between January and July 2016, "VIHSITAR strategy" was implemented in four clinics of HIV care, in four states of Mexico (Tlaxcala, Morelos, Sinaloa, Sonora). This strategy was based on the application of rapid tests for detection of HIV antibodies, syphilis, CD4+ cell counts through point of care kits, viral load as well as the active tuberculosis diagnosis, using a molecular biology test. Each participant was provided of pretest general information and post-counselling, essential elements to ensure linkage to care services. Sociodemographic and epidemiological variables were collected. We estimated prevalence of HIV, syphilis antibodies and tuberculosis. The time between diagnosis and incorporation of patients to care services were assessed, as well as the time of ART initiation. Results: 1688 people were screened. HIV prevalence was 12.5% (n = 211) (20.6% in men vs 3.5% in women, p = 0.00). Syphilis antibodies prevalence in people with HIV was 14.7% (n = 31) (16.5% in males, 3.4% in females p = 0.009), while active tuberculosis prevalence was 1.4% (n = 3). 85.4% of the people were linked to care in an average of 11 days (0-36); 68% occurred in the first 30 days after diagnosis, which showed a significant improvement compared with 2015 [2] (49%). 95% of the people linked to care, started ART (Figure 1 ). The mean of CD4 cells at diagnosis was 344 (156-487), the proportion of late diagnosis (CD4+ <200) was 30%, lower than the national average. No statistically significant differences were found between men and women group.
Conclusions: "VIHSITAR strategy" positioned detection as one of the main activities of the specialized units and succeeded in integrating the unit team into a systematized process. The promotion of the strategy contributed to increase the demand for detection. Knowing the immunological status immediately favoured the linkage to care services and to start ART. Definitely, the strategy contributed to improved detection and continuum of care.
approaches. We previously reported that 1/3 of first therapies in Latin America contained Zidovudine and more than 60% were Efavirenz based with large differences between countries. A very low rate of Raltegravir use was highlighted. The aim of this study is to determine the trend in patterns of ARV use in naïve patients of Latin American countries over the last three years. . There is slight trend to decrease Pi based regimens as first ART. Less than 2% of patients initiates ART with integrase inhibitors based regimens (Figures 1 and 2) . Conclusions: We observed a marked trend to abandon ZDV as part of the backbone in patients initiating ART. Integrase inhibitors are almost non included in first therapies in the region, may be for budgetary reasons on the contrary to the trend observed in developed countries. Standardization of first-line regimens is guaranteed in Latin America.
Introduction: HIV epidemic in the Dominican Republic (DR) is concentrated amongst key populations (KP), including MSM, transgender and migrants. Despite progress in development of HIV prevention interventions, still we register newly infections amongst these populations. There is a growing interest to evaluate the cascade of care per each KP, separately from general population (GP) and to monitor effectiveness of each intervention that might modify the continuum in care [1, 2] . The aim of this study was to evaluate a model of retention focused in key populations in the DR. Methods: We selected three outpatients HIV clinics in the country with more than 5000 patients to evaluate three interventions: early testing, opportune ART medication and viral suppression. We initiate KP despite CD4 count or viral load after psychological assessment, and developed a case navigator model for retention in care [3] . The model of retention included: case tracking and linkage to services, community-focused services and opportune provision of services on site (HIV/STIs screening, chemistry and screening for HPV infections). We collected data of testing, ART treatment and viral suppression. Results: HIV testing coverage was similar between GP and KP, but the number of positive results was greater in MSM, trans, TRSX and migrant populations (Figure 1 ). Linkage to care was achieved in 100% of positive cases. At the moment of evaluation 1766 patients were retained in care, and a total of 691 new patients were started in ART. Viral suppression was achieved in 80.2% of the patients (Figure 2) .
Conclusions: Implementation of community focused interventions for KP will increased the number of positive unknown results amongst most-at-risk populations by 18% (normal average in concentrated populations 2-5%), and an increased number of early provision of ART, and a sustained viral suppression will substantially reduce HIV transmission.
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Coverage of influenza vaccine (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) (Figure 1 ). We summarize in Table 1 . Conclusions: The annual coverage of influenza vaccine in PLWH receiving care in our centre is low. Reasons for lack of vaccination are unknown to us, but we can rule out lack of prescription, access or cost. Increasing age, being female and baseline low CD4 are associated to an increased probability of vaccination most seasons. This calls the attention to the need of strengthening primary care for PLWH; in particular, to improve vaccine coverage. Further knowledge about the reasons for lack of vaccination is needed.
Season
Age OR (95% CI) Sex OR (95% CI) ART OR (95% CI) CD4 OR (95% CI) confirmation may be inaccurate [1] . Timely and optimal identification and treatment of patients during the acute phase of HIV infection impact the long-term outcome of the individual and transmission [2] . Even though universal access to antiretroviral treatment (ART) exists in Mexico [3] , entering to care and initiating treatment in public institutions faces important bureaucratic, regulatory and administrative hurdles. These constitute barriers for rapid treatment initiation in patients presenting with acute HIV-infection. Acknowledging these limitations and identifying the bottlenecks in the process of linking patients to care and initiating ARV, a novel enrolment strategy was implemented in 2015 for patients with acute HIV-infection. Methods: Personnel from the key areas involved in the care of HIV patients in our hospital (infectious disease residents, attending physicians, social workers, nurses, laboratory and administrative personnel) were sensitized in the importance of prompt ART for acute HIV. An encrypted instant-messaging group was created with all the involved staff, with the purpose of eliciting an alert whenever any member participating in the chain of care became aware of a patient with probable acute HIV-infection. Once a probable case is identified in any area of the hospital covered by members of the group, a conversation is initiated to discuss the appropriate immediate steps with the purpose of confirming diagnosis, initiating ART as soon as possible and clearing the paperwork and administrative procedures with a high level of priority in all the steps.
Results: Since 2015, 20 patients with acute HIV-infection have been incorporated to care and initiated ART using this approach.
Patients have been followed for 10.21 ± 6.15 months. The median time to ART initiation was less than 24 h, when the median time for chronic patients is 40 days in our centre. At six months of follow-up, there was an 89% retention rate. Conclusions: By emphasizing instant communication and interdisciplinary approach in all involved personnel, ARV initiation for patients with acute HIV infection is immediate with a high level of retention in care. Longer follow-up is needed to determine the long-term impact of this new approach in these patients.
P040
HIV in older adults: prevalence and clinical characteristics Introduction: HIV in older adults represents a relatively new topic, with a marked increase in incidence and prevalence worldwide [1, 2] ; this has occurred because HIV diagnosis has increased in older people and on the other hand, HAART [3, 4] has helped HIV patients to get older [5] . The aim of this study was to determine the prevalence of older adults amongst the HIV patients in our cohort and to evaluate the clinical characteristics and evolution in comparison with younger patients.
Methods:
The study was performed including all the HIV patients enrolled in CAPASITS Leon during the period from 2007 to 2015. CAPASITS Leon is an HIV/AIDS clinic in León, Guanajuato, Mexico that provide attention to around 1200 HIV infected patients. The patients included were categorized into two groups: the younger patients (18-49 yo) and older adults (above 50 years of age). CD4+ count, viral load, clinical stage and the presence of opportunistic infections were analysed at the moment of diagnosis. Additionally, virologic and immunologic responses were evaluated after one year of HAART initiation. The search of the differences amongst categories was performed with the χ2 test, Student's t-test and Fisher's exact test, using IBM SPSS Statistics. Results: A total of 452 patients were included in the analysis, 47 (10,4%) of them were older adults; 384 (85%) were male and 239 (62,2%) of them were MSM. When comparing the groups, there was no difference in clinical staging or the presence of opportunistic infection at the diagnosis. There was no difference between younger and older patients when mean of CD4+ count was compared at the moment of diagnosis (316.4 vs 276.6 cells/µL; p = 0.868), and at the beginning of HAART (278.22 vs 231.94 cells/µL; p = 0.292). There was no difference in the mean CD4+ count after one year of HAART between younger and older patients (514.44 vs 455.11 cels/µl; p < 0.841) with similar increase in the CD4+ count during this time (236.21 vs 223.17 cels/µl; p < 0.869). Virologic response after one year of HAART was no different between younger and older patients with similar rates of virologic suppression (86% vs 85%, p = 0.879). Conclusions: In our study, people aged 50 and over accounted for 10% of the new HIV diagnosis. In contrast with other cohorts our older patients do not have differences in characteristics at diagnosis neither in the immunologic or virologic response when compared with younger patients.
proportion that were enrolled in care after 50 years. We assessed how these proportions changed over time. Results: There were 5505 patients 50 years or older enrolled in CCASAnet centres in seven countries in Latin America between 2000 and 2015. The proportion of people in care older than 50 years increased annually from 10% to 26% between 2000 and 2015. This proportion increased over time at similar rates in all sites, except Honduras (Figure 1) . Most of this growth is explained by the proportional increase of PLWH aging in care (Figure 2 ). Demographic and clinical characteristics at enrolment in care, and at enrolment in the 50 years cohort are described in Table 1 . In summary patients aging in care have a higher prevalence of NADEs before or at enrolment in the 50 years cohort, and longer time since diagnosis to ART initiation than those enrolled after 50 years. Conclusions: The proportion of PLWH older than 50 years receiving care in CCASAnet in Latin America has been steadily and significantly increasing in the past 15 years and currently composes 26% of our patients. This increase is primarily driven by the increasing population of people enrolled in care <50 years who have remained alive and in care after 50 years. NADEs in this population is highly prevalent at enrolment in the 50 years cohort. Planning for integrated care in this population should be a priority for health systems in the region.
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Trends in late presentation to care and presentation with advanced HIV disease in Latin America Introduction: Any delay in testing and ART initiation is associated to increased risk of transmission. Late presentation (CD4 <350 cells/µL) and especially presentation to care with advanced HIV disease (CD4 <200 cells/µL) increase risk of disease progression, hospitalization rates, costs and mortality. We previously reported 60% of late presentation amongst more than 6000 new HIV cases with 37% presenting with advanced disease, comparable to rates reported by PAHO and CCASAnet (38-45%). . Presentation to care with advanced disease was strongly related to age at presentation ranging from less than 25% in younger than 25 yo to close to 50% in older than 60 yo. On the contrary timely presentation to care decreased with age at diagnosis (Figure 1 ). Along the 3 observed years presentation to care with more than 500 CD4 does not exceed 20%. Conclusions: Late presentation to care and presentation with advanced HIV disease remain a big problem in Latin America as a direct consequence of insufficient testing in the region. This is especially the case for elderly people who are at increased risk to present to care very late. Strategies to increase testing are usually Abstract P042- Figure 1 . CD4 count at presentation to care by age.
OPPORTUNISTIC INFECTIONS
P044
Prevalence of fluconazole resistance in oropharyngeal candidiasis and clinical outcomes in a cohort of patients with HIV infection 16-64 μg/mL and resistant ≥64 μg/mL. The clinical response was assessed at the end of empirical treatment (14 days) and the presence of recurrences were measured at three months of enrolment. Descriptive statistics were calculated and percentages were reported in categorical variables and median with interquartile range (IQR) in numerical variables. Results: Fifty-three patients were included from February to November 2016: 62.2% were men, mean age was 41 years (SD± 11), with a median CD4+ lymphocyte count of 77 cells/μL (IQR: 23-154). 22.6% of subjects were on HAART. Clinical findings were: 51 pseudomembranous, 1 angular cheilitis and 1 atrophic candidiasis. In 20, 7% (11/53) individuals had already received at least one dose of fluconazole at the time of swabbing and 21 patients had been treated with azoles for previous episodes of candidiasis. Chromogenic identification showed the following: 46 were C. albicans, 11 other species (six C. tropicalis, three C. glabrata, two C. krusei). In three patients more than one species were isolated. To date, antifungal susceptibility testing was performed for 15 isolates: 1 had MIC value of 128 μg/mL and another of 16 μg/mL, the remaining 13 had MIC values of 7 patients had persistent oropharyngeal candidiasis, 2 of the isolates were C. tropicalis and 5 C. albicans. The cumulative incidence of recurrences was 16.9% (9/53). All isolates were C. albicans, one of them was considered azole resistant according to MIC value. Conclusions: In our study, previous exposure to fluconazole was frequent and emerging non-albicans species were common. The preliminary prevalence of resistance or SDD was greater than 10%.
Asistencia Científica/Infectoclínicos, Bogotá, Colombia.
Abstract P045- Table 1 . Virologic Outcomes at Weeks 24 and 48. Introduction: HIV infection and AIDS remain a major public health problem worldwide. Despite highly active antiretroviral therapy (HAART) has dramatically improved the prognosis of people living with HIV (PLHIV); mortality due to AIDS is still an important issue, mostly related to gaps in HIV diagnosis and timing of ART initiation. Methods: We conducted a retrospective, analytical cohort study with the HIV /AIDS patient database from the HIV /AIDS Epidemiological Surveillance System for the period 2000-2014.
The variables included were those obtained from the case epidemiological study, of the notifying units. We calculated KM analysis to estimate survival. We then stratified survival according to CD4+ cell count at ART initiation. Late ART initiation was defined as starting therapy with CD4+ cell counts under 200 cells/mm 3 . Timely initiation was described as ART started with CD4+ cell counts over 200 cells/mm 3 . KM estimators were compared between the two groups. Results: A total of 43,125 HIV-positive patients were registered in the database and had useful information for the analysis. Of those, 2494 (5.78%) deaths were registered; the remaining 40,631 (94.22%) patients were still alive. Seventeen per cent (7367) subjects had late ART initiation. 26% of those in the late HAART initiation group had died, versus 2% of patients initiating HAART timely (p < 0.001). Late HAART initiation resulted in a relative risk of dying of 15.18 (95% CI: 13.90-16.58, p < .0.001), when compared to those initiating in a timely manner. Deaths occurring in the late HAART initiation group were mostly observed within the first four years of the disease (79.63%). The calculated etiologic fraction amongst those with late ART initiation was 0.93; which represents the proportion of preventable deaths with timely ART initiation. Calculated poblational etiologic fraction was 0.70. Conclusions: Although data presented in this study just confirm those previously found in several studies; our results conclude that an important proportion of mortality due to HIV in Mexico could be prevented with timely diagnosis and shortening of ART initiation periods. Better surveillance systems are urgently needed in our country to improve the quality of these data and optimize diagnosis and treatment initiation amongst PLWH. Introduction: In Cuba, more than 70% of patients are currently under antiretroviral (ARV) therapy. In the year 2009 ARV resistance and subtype surveillance was introduced in routine clinical practice. This work aims to investigate the level and profile of ARV resistance and subtype distribution amongst HIV-1 patients failing therapy. Methods: The study compiled data of subtype and genotypic resistance analysis performed to 756 samples of HIV-1 patients taken between April 2009 and December 2016 in Cuba (STI Laboratory, Institute of Tropical Medicine "Pedro Kourí"). HIV-1 subtype was determined with Rega Subtyping Tool v.3 and confirmed by manual phylogenetic analysis. Drug resistance interpretation was conducted using the resistance interpretation algorithm Rega v9.1.0. For statistical analysis, the software package SPSS v.19 was used. Results: The most prevalent HIV-1 genetic forms were subtype B (30.6%), BG recombinants (22.7%) and CRF19_cpx (19.3%). Subtype B was more prevalent in MSM (p < 0.001), while Subtypes A, F, G Medizinisches Infektiologie Zentrum, Berlin, Germany Introduction and aims: Optimal duration of therapy to achieve SVR depends on multiple factors. Patients treated with LDV/SOF with 8-24 weeks achieved SVR12 from 94% to 100% in the ION phase 3 studies. A decision to shorten therapy to 8 weeks is based on treatment history, cirrhosis status and baseline VL. In a post-hoc analysis of the ION-3 (TN, NC patients) 8 week data, a VL <6M was the best predictor of SVR. RWE is often different from Phase III trials and there is a need to understand real-world 8 week regimens in a broader spectrum of patients. Methods: RWE 8 week LDV/SOF data is emerging from multiple single-centre and multicentre retrospective and prospective cohorts. In this analysis, the phase-3 ION-3 data is compared with data from several diverse real world populations and one postmarketing investigator sponsored HIV/HCV trial. Patient demographics, characteristics, SVR12 and discontinuation data has been collated and compared. Results: The ION-3 post-hoc analysis reported 123 patients who were TN, NC and VL<6 M and treated with 8 weeks of LDV/SOF. Mean age was 52, 22% black, 72% GT1a; the SVR12 was 97% (119/ 123) ( Table 1 ). The overall SVR12 rate from six diverse real world and post marketing cohorts was also 98% (1726/1767). There was no significant impact of HCV genotypes or subtypes (GT1a, 1b Abstract P049- Figure 2 . SVR12 in genotype 1b (ITT).
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Abstract P050- Twenty fold more GFP expression of infected cells over noninfected using a fluorescence microscope. Previously described TRT phenotypic assay with pNL4.3ΔV was also performed [1] .
Results: Recombinant viruses containing V3 region from pNL4.3 and pNLAD8 showed GFP expression only in Ghost (3) CXCR4 cells and Ghost (3) Hi5 cells, respectively, consistent with the known coreceptor specificity for these strains. There was no GFP expression in mock cells. TRT assay was also performed with reference strains; pNL4.3, and results were in concordance with our assay.
Conclusions:
We have successfully developed a phenotypic assay based on V3 region of gp120 only, further strengthening the tropism prediction capacity of V3 alone. Small fragment size used here, in comparison to standard assays, makes the laboratory amplification more efficient. The assay eliminates the selective bias associated with selection of X4 viruses in cultures and could be validated to use with proviral DNA, providing advantage for tropism testing of patients with undetectable viremia. Validation of this assay with clinical samples compared to gold standard methods is warranted.
